Perseus Proteomics (TSE:4882) Total Current Liabilities: 円65.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4882 Perseus Proteomics Inc TSE:4882
56 GF Score
Price 円160.00
GF Value 円439.72
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Perseus Proteomics Total Current Liabilities?

Perseus Proteomics TSE:4882 +2.56% 56 Total Current Liabilities is 円65.4 Mil as of Mar. 2026. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.72 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Perseus Proteomics's total current liabilities for the quarter that ended in Mar. 2026 was 円65.4

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Perseus Proteomics Total Current Liabilities Related Terms

Perseus Proteomics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Perseus Proteomics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perseus Proteomics Total Current Liabilities Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only 148.38 111.12 128.98 124.87 65.44

Perseus Proteomics Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.98 136.58 124.87 97.30 65.44
TSE:4882
56GF Score
Perseus Proteomics Inc TSE:4882
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perseus Proteomics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Perseus Proteomics's Total Current Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=27.831+0
+Other Current Liabilities+Current Deferred Liabilities
=37.61+0
=65.4

Perseus Proteomics's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=27.831+0
+Other Current Liabilities+Current Deferred Liabilities
=37.61+0
=65.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of 円65.4 Mil mean?
Perseus Proteomics (TSE:4882) has a Total Current Liabilities of 円65.4 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Perseus Proteomics and its competitors.
Is Perseus Proteomics' Total Current Liabilities too high?
Perseus Proteomics' current Total Current Liabilities is 円65.4 Mil. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Total Current Liabilities compare to LLY and JNJ?
Perseus Proteomics' Total Current Liabilities of 円65.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Perseus Proteomics and its competitors. Perseus Proteomics's current Total Current Liabilities is 円65.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.72, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current Total Current Liabilities is 円65.4 Mil. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Total Current Liabilities is 円65.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Perseus Proteomics (TSE:4882) Overvalued in 2026?

Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued. The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.72. GuruFocus considers Perseus Proteomics to be Significantly Undervalued.

Key valuation signals for TSE:4882:

  • Total Current Liabilities: 円65.4 Mil
  • GF Value™: 円439.72 vs. price of 円160.00 (63.6% below fair value)
  • GF Score™: 56/100 with 1 warning sign

No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Perseus Proteomics Business Description

Address 30-1 Hakozakicho, Nihonbashi, Chuo-ku, AiNihombashi EAST 3rd floor, Tokyo, JPN, 103-0015
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score

Get the complete analysis for TSE:4882

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円160.00
Price
円439.72
GF Value